Routine

Polypharmacy & deprescribing (medication review; STOPP/START, anticholinergic burden)

Medication safety · Geriatric & General
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Polypharmacy (commonly >=5 regular medicines) is problematic when the harms outweigh benefit: adverse drug reactions, drug-drug and drug-disease interactions, falls, delirium, bleeding, AKI, hospital admission and poor adherence. Deprescribing is the planned, supervised, patient-centred process of reducing or stopping drugs that are no longer of benefit or may be causing harm. It is a core geriatric intervention and should be considered at every admission, discharge and medication review.

Red flags

  • Recent fall, delirium, bleeding or AKI temporally linked to a drug
  • Hypoglycaemia on sulfonylurea/insulin in a frail patient
  • Serotonin syndrome / anticholinergic toxidrome from combined agents
  • Bradycardia/hypotension from accumulating cardiac drugs in renal impairment
  • Withdrawal syndromes from abrupt cessation (seizures from benzodiazepine withdrawal, adrenal crisis from steroid withdrawal)

Assessment

Differential diagnosis

  • Adverse drug reaction mimicking new disease (prescribing cascade — e.g. amlodipine oedema treated with a diuretic)
  • Drug-induced falls/delirium/confusion
  • Drug-induced AKI (triple whammy: ACEi/ARB + diuretic + NSAID)
  • Anticholinergic toxicity (dry mouth, constipation, retention, cognitive impairment)
  • Non-adherence due to pill burden

Investigations

  • Full reconciled medication list (include OTC, herbal, inhalers, eye drops, topical, as-required)
  • U&E/eGFR (dose adjustment, nephrotoxic combinations), LFTs, FBC
  • Calculate anticholinergic burden (ACB score); identify high-risk drugs
  • Apply explicit tools: STOPP/START criteria, Beers criteria, NO TEARS, drug-burden index
  • Check indication, ongoing benefit and intended duration for EACH drug
  • Postural BP, HbA1c, INR/anticoagulation review as relevant

Management

  • Reconcile the full list and establish what the patient actually takes and their priorities/goals
  • For each drug ask: is there a current valid indication? Is it still achieving benefit? Do harms/risks outweigh benefit given life expectancy and goals? Is the dose appropriate for renal/hepatic function?
  • Identify drugs to target first: those causing harm now, no indication, duplicates, high anticholinergic burden, drugs with no benefit given limited prognosis, and unresolved prescribing cascades
  • Prioritise with the patient; stop one or a few at a time where possible to allow monitoring
  • Taper drugs that need it (benzodiazepines, Z-drugs, opioids, gabapentinoids, SSRIs/SNRIs, beta-blockers, PPIs, corticosteroids, antipsychotics) to avoid withdrawal/rebound
  • Document rationale, plan and monitoring; communicate clearly to patient, carer and GP
  • Arrange follow-up to review symptoms, withdrawal effects and whether a drug needs restarting
  • Use START criteria to also identify under-prescribing (e.g. missing bone protection, anticoagulation in AF, statin where indicated)

Drugs & doses

Common deprescribing targets (older/frail): benzodiazepines & Z-drugs (falls, cognition), 'z' and long-acting sulfonylureas (hypoglycaemia), NSAIDs (GI/renal/CV), long-term PPIs without indication, anticholinergics (oxybutynin, amitriptyline, promethazine), antipsychotics in dementia, long-term opioids/gabapentinoids [verify local]
Taper examples: benzodiazepine reduce by ~1/8 of dose every 1-2 weeks; long-term oral prednisolone wean per HPA-axis risk; PPI step down then alternate-day then stop [verify local dose]
Avoid the 'triple whammy': ACE inhibitor/ARB + diuretic + NSAID (AKI risk) — stop the NSAID
Beware prescribing cascades: calcium-channel-blocker oedema, metoclopramide/antipsychotic parkinsonism, PPI-induced hypomagnesaemia

Disposition

Outpatient/structured medication review (GP, pharmacist) or inpatient at admission/discharge. Ensure clear communication of changes and monitoring plan to primary care; safety-net for withdrawal effects.

Complications & pitfalls

  • Adverse drug withdrawal events / rebound (hypertension, reflux, insomnia, anxiety, pain)
  • Return of the treated condition if stopped inappropriately
  • Adrenal crisis if long-term steroids stopped abruptly
  • Patient/carer anxiety and loss of confidence if not well communicated

Exam pearls

  • Tools: STOPP/START v3, Beers criteria, anticholinergic burden (ACB) scale, NICE multimorbidity guidance (NG56).
  • Deprescribing is not 'doing nothing' — it is active, monitored care with follow-up.
  • Match treatment intensity to life expectancy and goals: statins, tight glycaemic/BP targets and bisphosphonates may offer little benefit in limited prognosis.
  • Always taper the 'A-B-C-D-G-O' drugs (antidepressants, benzodiazepines, corticosteroids, dopaminergics, gabapentinoids, opioids) and PPIs/beta-blockers.
  • Every prescribing cascade is an opportunity to deprescribe the original culprit.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.